Natco Pharma Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1376.40 +10.25 (0.75%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1366.15
Today’s High
1389.35
52 Week Low
752.55
52 Week High
1638.35
1374.75 +10.10 (0.74%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1361.75
Today’s High
1389
52 Week Low
752.45
52 Week High
1639
Key Metrics
- Market Cap (In Cr) 24442.23
- Beta 0.66
- Div. Yield (%) 0.42
- P/B 4.18
- TTM P/E 13.08
- Peg Ratio 0.27
- Sector P/E 31.15
- D/E 0.03
- Open Price 1377.95
- Prev Close 1366.15
Natco Pharma Analysis
Price Analysis
-
1 Week-2.19%
-
3 Months-5.33%
-
6 Month36.57%
-
YTD68.19%
-
1 Year74.75%
Risk Meter
- 33% Low risk
- 33% Moderate risk
- 33% Balanced Risk
- 33% High risk
- 33% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 2
- 2
- 2
- Buy
- 2
- 2
- 2
- 1
- Hold
- 2
- 2
- 2
- 2
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 8
- 9
- 9
- 8
Natco Pharma News
Pankaj Pandey of ICICI Securities recommends these 5 shares to buy for long term
5 min read . 08:39 AM ISTStocks to Watch: Nykaa, Hyundai Motor, BSE, Zydus Life, Sunteck Realty, and more
3 min read . 13 Nov 2024Stock market today: Five stocks to buy or sell in Muhurat trading
5 min read . 01 Nov 2024Natco Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 3998.8
- Selling/ General/ Admin Expenses Total
- 525
- Depreciation/ Amortization
- 186.8
- Other Operating Expenses Total
- 1005.8
- Total Operating Expense
- 2434.2
- Operating Income
- 1564.6
- Net Income Before Taxes
- 1673.5
- Net Income
- 1388.3
- Diluted Normalized EPS
- 77.34
- Period
- 2024
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.2
- Period
- 2024
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023
- Total Revenue
- 2707.1
- Selling/ General/ Admin Expenses Total
- 996.2
- Depreciation/ Amortization
- 163.8
- Other Operating Expenses Total
- 11.4
- Total Operating Expense
- 1930.1
- Operating Income
- 777
- Net Income Before Taxes
- 861.9
- Net Income
- 715.3
- Diluted Normalized EPS
- 38.48
- Period
- 2023
- Total Assets
- 5657.4
- Total Liabilities
- 783.6
- Total Equity
- 4873.8
- Tangible Book Valueper Share Common Eq
- 256.81
- Period
- 2023
- Cashfrom Operating Activities
- 849.1
- Cashfrom Investing Activities
- -477.1
- Cashfrom Financing Activities
- -363
- Net Changein Cash
- 20.8
- Period
- 2022
- Total Revenue
- 1944.8
- Selling/ General/ Admin Expenses Total
- 895.6
- Depreciation/ Amortization
- 142.6
- Other Operating Expenses Total
- 17.2
- Total Operating Expense
- 1823.9
- Operating Income
- 120.9
- Net Income Before Taxes
- 202.2
- Net Income
- 170
- Diluted Normalized EPS
- 7.35
- Period
- 2022
- Total Assets
- 5109.1
- Total Liabilities
- 845.5
- Total Equity
- 4263.6
- Tangible Book Valueper Share Common Eq
- 226.31
- Period
- 2022
- Cashfrom Operating Activities
- 46.5
- Cashfrom Investing Activities
- -5.3
- Cashfrom Financing Activities
- 34.8
- Net Changein Cash
- 85.3
- Period
- 2021
- Total Revenue
- 2052.1
- Selling/ General/ Admin Expenses Total
- 864.2
- Depreciation/ Amortization
- 116.9
- Other Operating Expenses Total
- 11.8
- Total Operating Expense
- 1562.8
- Operating Income
- 489.3
- Net Income Before Taxes
- 579.6
- Net Income
- 440.9
- Diluted Normalized EPS
- 22.82
- Period
- 2021
- Total Assets
- 4791.9
- Total Liabilities
- 670.3
- Total Equity
- 4121.6
- Tangible Book Valueper Share Common Eq
- 225.53
- Period
- 2021
- Cashfrom Operating Activities
- 298.8
- Cashfrom Investing Activities
- -103.3
- Cashfrom Financing Activities
- -185.7
- Net Changein Cash
- 6
- Period
- 2020
- Total Revenue
- 1915
- Selling/ General/ Admin Expenses Total
- 809.1
- Depreciation/ Amortization
- 99.8
- Other Operating Expenses Total
- 23.5
- Total Operating Expense
- 1432.2
- Operating Income
- 482.8
- Net Income Before Taxes
- 568.7
- Net Income
- 460.8
- Diluted Normalized EPS
- 24.54
- Period
- 2020
- Total Assets
- 4587.8
- Total Liabilities
- 814.3
- Total Equity
- 3773.5
- Tangible Book Valueper Share Common Eq
- 206.77
- Period
- 2020
- Cashfrom Operating Activities
- 417.3
- Cashfrom Investing Activities
- -167
- Cashfrom Financing Activities
- -250.8
- Net Changein Cash
- -8.5
- Period
- 2019
- Total Revenue
- 2094.5
- Selling/ General/ Admin Expenses Total
- 801
- Depreciation/ Amortization
- 81
- Other Operating Expenses Total
- 10.1
- Total Operating Expense
- 1378.5
- Operating Income
- 716
- Net Income Before Taxes
- 824.7
- Net Income
- 644.4
- Diluted Normalized EPS
- 34.31
- Period
- 2019
- Total Assets
- 4303.1
- Total Liabilities
- 814.1
- Total Equity
- 3489
- Tangible Book Valueper Share Common Eq
- 190.44
- Period
- 2019
- Cashfrom Operating Activities
- 668.8
- Cashfrom Investing Activities
- -612.2
- Cashfrom Financing Activities
- -50.9
- Net Changein Cash
- 6.6
- Period
- 2018
- Total Revenue
- 2202
- Selling/ General/ Admin Expenses Total
- 730.2
- Depreciation/ Amortization
- 66.2
- Other Operating Expenses Total
- 8.4
- Total Operating Expense
- 1339.8
- Operating Income
- 862.2
- Net Income Before Taxes
- 887.2
- Net Income
- 696.2
- Diluted Normalized EPS
- 38.67
- Period
- 2018
- Total Assets
- 3715.1
- Total Liabilities
- 642.9
- Total Equity
- 3072.2
- Tangible Book Valueper Share Common Eq
- 166.2
- Period
- 2018
- Cashfrom Operating Activities
- 463.6
- Cashfrom Investing Activities
- -1115.5
- Cashfrom Financing Activities
- 650.9
- Net Changein Cash
- -1.8
- Period
- 2024-09-30
- Total Revenue
- 1371.1
- Selling/ General/ Admin Expenses Total
- 151.5
- Depreciation/ Amortization
- 45.8
- Other Operating Expenses Total
- 237.7
- Total Operating Expense
- 612.6
- Operating Income
- 758.5
- Net Income Before Taxes
- 818.2
- Net Income
- 677.3
- Diluted Normalized EPS
- 37.81
- Period
- 2024-09-30
- Total Assets
- 8244.7
- Total Liabilities
- 1094.8
- Total Equity
- 7149.9
- Tangible Book Valueper Share Common Eq
- 385.93
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1137
- Cashfrom Investing Activities
- -881.7
- Cashfrom Financing Activities
- -219.1
- Net Changein Cash
- 34.2
- Period
- 2024-06-30
- Total Revenue
- 1362.6
- Selling/ General/ Admin Expenses Total
- 142
- Depreciation/ Amortization
- 44.1
- Other Operating Expenses Total
- 235.6
- Total Operating Expense
- 601.9
- Operating Income
- 760.7
- Net Income Before Taxes
- 803.6
- Net Income
- 668.5
- Diluted Normalized EPS
- 37.32
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1068.3
- Selling/ General/ Admin Expenses Total
- 142.5
- Depreciation/ Amortization
- 55.5
- Other Operating Expenses Total
- 285.9
- Total Operating Expense
- 626.5
- Operating Income
- 441.8
- Net Income Before Taxes
- 477.6
- Net Income
- 386.3
- Diluted Normalized EPS
- 21.56
- Period
- 2024-03-31
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.2
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023-12-31
- Total Revenue
- 758.6
- Selling/ General/ Admin Expenses Total
- 121.9
- Depreciation/ Amortization
- 44.2
- Other Operating Expenses Total
- 206.4
- Total Operating Expense
- 534.7
- Operating Income
- 223.9
- Net Income Before Taxes
- 256.3
- Net Income
- 212.7
- Diluted Normalized EPS
- 11.88
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1031.4
- Selling/ General/ Admin Expenses Total
- 122.4
- Depreciation/ Amortization
- 43.6
- Other Operating Expenses Total
- 235.2
- Total Operating Expense
- 617
- Operating Income
- 414.4
- Net Income Before Taxes
- 439.6
- Net Income
- 369
- Diluted Normalized EPS
- 20.6
- Period
- 2023-09-30
- Total Assets
- 6254
- Total Liabilities
- 960.5
- Total Equity
- 5293.5
- Tangible Book Valueper Share Common Eq
- 284.47
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 632.3
- Cashfrom Investing Activities
- -347.8
- Cashfrom Financing Activities
- -314.4
- Net Changein Cash
- -27.9
- Period
- 2023-06-30
- Total Revenue
- 1140.5
- Selling/ General/ Admin Expenses Total
- 138.2
- Depreciation/ Amortization
- 43.5
- Other Operating Expenses Total
- 278.3
- Total Operating Expense
- 656
- Operating Income
- 484.5
- Net Income Before Taxes
- 500
- Net Income
- 420.3
- Diluted Normalized EPS
- 23.26
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 897.9
- Selling/ General/ Admin Expenses Total
- 118.9
- Depreciation/ Amortization
- 41
- Other Operating Expenses Total
- 181.5
- Total Operating Expense
- 599.8
- Operating Income
- 298.1
- Net Income Before Taxes
- 324.4
- Net Income
- 275.8
- Diluted Normalized EPS
- 15.1
- Period
- 2023-03-31
- Total Assets
- 5657.4
- Total Liabilities
- 783.6
- Total Equity
- 4873.8
- Tangible Book Valueper Share Common Eq
- 256.81
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 849.1
- Cashfrom Investing Activities
- -477.1
- Cashfrom Financing Activities
- -363
- Net Changein Cash
- 20.8
- Period
- 2022-12-31
- Total Revenue
- 492.5
- Selling/ General/ Admin Expenses Total
- 105.6
- Depreciation/ Amortization
- 41.5
- Other Operating Expenses Total
- 165.6
- Total Operating Expense
- 428.1
- Operating Income
- 64.4
- Net Income Before Taxes
- 81.4
- Net Income
- 62.3
- Diluted Normalized EPS
- 3.41
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Natco Pharma Technical
Moving Average
SMA
- 5 Day1371.73
- 10 Day1395.85
- 20 Day1376.06
- 50 Day1424.98
- 100 Day1388.44
- 300 Day1191.05
Natco Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Laurus Labs
- 489.25
- 0.1
- 0.02
- 517.9
- 358.7
- 26368.9
- JB Chemicals & Pharmaceuticals
- 1715
- 49.1
- 2.95
- 2029
- 1376.95
- 26617.05
- Natco Pharma
- 1376.4
- 10.25
- 0.75
- 1638.35
- 752.55
- 24637.56
- Alembic Pharmaceuticals
- 1038.4
- -4.2
- -0.4
- 1296.15
- 710.5
- 20411.11
- Wockhardt
- 1158.2
- -28.75
- -2.42
- 1334.55
- 321
- 17836.28
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Laurus Labs
- 162.98
- 6.41
- 20.68
- 12.83
- JB Chemicals & Pharmaceuticals
- 47.82
- 8.85
- 20.54
- 16.06
- Natco Pharma
- 17.63
- 4.18
- 14.63
- 25.16
- Alembic Pharmaceuticals
- 33.3
- 4.24
- 15.94
- 12.47
- Wockhardt
- -
- 5.41
- -10.63
- -12.7
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Nov-24
- Quarterly Results & Interim Dividend
- 12-Aug-24
- Quarterly Results & Interim Dividend
- 27-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results & Interim Dividend
- 14-Nov-23
- Quarterly Results & Interim Dividend
- 09-Aug-23
- Quarterly Results & Interim Dividend
- 29-May-23
- Audited Results
- 08-Mar-23
- Buy Back of shares
- 09-Feb-23
- Quarterly Results & Interim Dividend
- 10-Nov-22
- Quarterly Results & 2nd Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 28-Mar-24
- 22-Feb-24
- POM
- 29-Sept-23
- 05-Sept-23
- AGM
- 27-Mar-22
- 22-Feb-22
- POM
- -
- 12-Aug-24
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-Nov-24
- 27-Nov-24
- 27-Nov-24
- 1.5
- 12-Aug-24
- 23-Aug-24
- 23-Aug-24
- 3
- 14-Feb-24
- 26-Feb-24
- 26-Feb-24
- 1.25
- 15-Nov-23
- 24-Nov-23
- 24-Nov-23
- 1.25
- 09-Aug-23
- 22-Aug-23
- 22-Aug-23
- 7
- 09-Feb-23
- 21-Feb-23
- 21-Feb-23
- 1.25
- 10-Nov-22
- 22-Nov-22
- 21-Nov-22
- 0.75
- 10-Aug-22
- 22-Aug-22
- 19-Aug-22
- 3.5
- 14-Feb-22
- 25-Feb-22
- 24-Feb-22
- 2
- 11-Nov-21
- 24-Nov-21
- 23-Nov-21
- 0.5